Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

Inclusion Criteria:

• Participant has received a commercially available Bristol-Myers Squibb (BMS)manufactured Gene Modified Cell Therapy (GMCT) and has been diagnosed with aqualifying second primary malignancy or a second primary malignancy which BMS hasqualified for testing.

• Participant has received a commercially available BMS manufactured GMCT in aclinical trial or other investigational setting (including non-conforming product)for which there is no testing protocol in place for that trial or investigationalsetting and has been diagnosed with a qualifying second primary malignancy or asecond primary malignancy which BMS has qualified for testing.

Exclusion Criteria:

• Participant is actively participating in a clinical trial where information andsample collection is being conducted under that clinical trial.

• Participant has not received a BMS manufactured GMCT or has not been diagnosed witha qualifying second primary malignancy.